After the conclusions reached in that study, I would think that someone would be interested enough to do some serious trials with younger subjects, if for no other reason, just to get their name on an easy-to-do research study. Surely, with all the money being made off the sales of probiotic products these days, there should be plenty of research money available for the asking, and a huge incentive to prove that the products do indeed have some value. I'm guessing that there is enough research expertise around to allow someone to come up with a creative way to put a positive spin on the next project.
But that may not be an easy task, despite all the money available to promote it. This isn't the first negative news for treatments that utilize the manipulation of gut bacteria populations in order to attempt to restore digestive system health. The use of prebiotics by IBD patients was soundly discredited a couple of years earlier. From page 52 of my book:
Prebiotics, which are soluble fiber products that pass undigested through the stomach and small intestine, into the colon, where they are fermented by bacteria, include fructo-oligosaccharides (FOS) and inulin fiber. The theory is that the fermentation of these items should help to feed beneficial bacteria and thereby help to reestablish healthy populations of beneficial gut bacteria. Unfortunately, no valid scientific research exists to show that prebiotics are any more likely to promote the growth of beneficial bacteria than pathogenic bacteria. In fact, a random, double blind trial, using FOS as a proposed treatment for Crohn’s disease, showed absolutely no benefits.15 Almost four times as many participants receiving FOS, compared with controls, withdrew from the trial before the end of the period. That implies a significant percentage of adverse results for the FOS group. Consequently, it should not be surprising that the use of prebiotics by someone with MC usually results in unpredictable effects at best, and undesirable effects at worst.
Where reference 15 is:
15. Benjamin, J. L., Hedin, C. R., Koutsoumpas, A., Ng, S. C., McCarthy, N. E., Hart, A. L., . . . Lindsay, J. O. (2011). Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut, 60(7), 923–929. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/21262918
I suspect that the handwriting is on the wall for other patient groups (age brackets) for which the use of probiotics is promoted, also. But as
they always say, more research is needed (which, of course, can be literally translated to mean that no medical research can be trusted enough to assume that it is the final word on anything).
Tex